Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFV

International Journal of Cancer

Volumn 88, Issue 6, 2000, Pages 962-969

  Kuan, Chien Tsun ^a   Wikstrand, Carol J ^a   Archer, Gary ^a   Beers, Richard ^b   Pastan, Ira ^b   Zalutsky, Michael R ^a   Bigner, Darell D ^a  

^a DUKE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 125; IODINE 131;

ANIMAL CELL; ANTIBODY LABELING; ARTICLE; BINDING AFFINITY; CELL SURFACE; FLOW CYTOMETRY; GLIOMA; IMMUNOREACTIVITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; XENOGRAFT;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; CELL MEMBRANE; FEMALE; GLIOMA; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTOXINS; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034672302     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(20001215)88:6<962::AID-IJC20>3.0.CO;2-U     Document Type: Article

References (36)

1. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-cerbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation
2. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies
3. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu
4. scFv multimers of the anti-neuraminidase antibody NC10: Length of the linker between VH and VL domains dictates precisely the transition between diabodies and triabodies
5. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display
6. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2
7. Single-chain antigen binding proteins
8. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice
9. Evaluation of radioiodinated and radiocopper labeled monovalent fragments of monoclonal antibody chCE7 for targeting of neuroblastoma
10. Effects of genetic engineering on the pharmacokinetics of antibodies
11. Pharmacokinetics and biodistribution of genetically-engineered antibodies
12. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue
13. The use of biosensor technology for the engineering of antibodies and enzymes
14. Single-chain Fv radioimmunotargeting
15. Protein engineering of antibody binding sites: Recovery of specific activity in an anti-dogoxigenin single-chain Fv analogue produced in Escherichia coli
16. Chemical modification to reduce renal uptake of disulfide-bonded variable region fragment of anti-Tac monoclonal antibody labeled with 99mTc
17. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics
18. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts
19. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors
20. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
21. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display
22. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
23. Single-chain Fvs
24. Recombinant antibody fusion proteins for cancer immunotherapy
25. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: Radioiodination method enhances cellular retention and uptake in tumor xenografts
26. Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate
27. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate
28. Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions
29. Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection
30. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site
31. Kinetics, competition, and selectivity of tubular absorption of proteins
32. Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis
33. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII
34. Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers
35. CDR walking mutagenesis for the affinity maturation of a human anti-HIV-1 antibody into the picomolar range
36. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms